Osimertinib in NSCLC: Real-World Data From New Zealand

Osimertinib in NSCLC: Real-World Data From New Zealand

Introduction: EGFR tyrosine kinase inhibitors (TKIs) are more effective than chemotherapy in patients with EGFR-mutant NSCLC. Disease progression on EGFR TKI therapy occurs most often owing to acquired resistance from the gain of an EGFR T790M mutation. Osimertinib, a third-generation EGFR TKI, sign...

Full description

Bibliographic Details
Main Authors: Yeojeong Jane So, MbChB, FRACP, Anne Fraser, MA, Gareth Rivalland, MbChB, FRACP, Mark McKeage, PhD, Richard Sullivan, MbChB, FRACP, Laird Cameron, MbChB, FRACP
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
T790M mutation
Epidermal growth factor receptor
Tyrosine kinase inhibitor
New Zealand
Osimertinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300229

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300229

Similar Items